Ensysce Biosciences (ENSC) Notes Payables (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Notes Payables of $306708.0 for Q4 2025, up 1.67% year-over-year from $301660.0 in Q4 2024, and down 20.89% quarter-over-quarter from $387702.0 in Q3 2025.
Ensysce Biosciences (ENSC) Notes Payables (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Notes Payables for 6 consecutive years, with $306708.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Notes Payables rose 1.67% year-over-year to $306708.0; the TTM figure through Dec 2025 stood at $306708.0 (up 1.67% YoY), while the FY2025 annual figure was $306708.0, up 1.67% from the prior year.
- Notes Payables declined to $306708.0 in Q4 2025 per ENSC's latest filing, from $387702.0 in the prior quarter.
- Across five years, Notes Payables topped out at $12.7 million in Q4 2021 and bottomed at $245973.0 in Q1 2024.
- Historically, Notes Payables has averaged $2.7 million across 5 years, with a median of $445738.0 in 2023.
- Annual changes were most pronounced in 2021 — Notes Payables soared 200.3% — and 2023, when it tumbled 95.35%.
- Ensysce Biosciences' Notes Payables stood at $12.7 million in 2021, then sank by 66.53% to $4.3 million in 2022, then tumbled by 79.97% to $854697.0 in 2023, then plunged by 64.71% to $301660.0 in 2024, then climbed by 1.67% to $306708.0 in 2025.
- Business Quant data shows ENSC's Notes Payables at $306708.0 in Q4 2025, $387702.0 in Q3 2025, and $424521.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - |
| 10 | Ensysce Biosciences | 933,442.63 | -3.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 306,708.00 |
| Sep 30, 2025 | 387,702.00 |
| Jun 30, 2025 | 424,521.00 |
| Mar 31, 2025 | 257,383.00 |
| Dec 31, 2024 | 301,660.00 |
| Sep 30, 2024 | 387,176.00 |
| Jun 30, 2024 | 454,463.00 |
| Mar 31, 2024 | 245,973.00 |
| Dec 31, 2023 | 854,697.00 |
| Sep 30, 2023 | 350,932.00 |
| Jun 30, 2023 | 445,738.00 |
| Dec 31, 2022 | 4.27 Mn |
| Sep 30, 2022 | 7.55 Mn |
| Jun 30, 2022 | 8.00 Mn |
| Mar 31, 2022 | 6.07 Mn |
| Dec 31, 2021 | 12.75 Mn |
| Sep 30, 2021 | 2.80 Mn |
| Dec 31, 2020 | 4.25 Mn |